ReviewCurrent atherosclerosis reports2025
Inflammation-Driven Plaque Erosion in Atherosclerosis: A Focus on Complement System Pathways.
Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The C-reactive protein-albumin-lymphocyte (CALLY) index as a predictor of mortality in patients undergoing carotid artery stenting.Irish journal of medical science · 2026Article
- Article
- Functional Heterogeneity of Immune Cell Subpopulations in Atherosclerosis: From Basic Mechanisms to Precision Therapy.Reviews in cardiovascular medicine · 2026Review
- Integrative statistical genetics prioritizes candidate ASCVD susceptibility genes across tissues.Molecular medicine (Cambridge, Mass.) · 2026Article
- Early Identification of ST-Segment Elevation Myocardial Infarction (STEMI) at Presentation: Comparative Diagnostic Performance of CBC-Derived Inflammatory Indices and High-Sensitivity Troponin T.Journal of clinical medicine · 2026Article
- CD8Nature reviews. Cardiology · 2026Review
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- Integrative genetic and expression profiling prioritizesFrontiers in immunology · 2026Article
- Peripheral Blood HIST1H2AE is a Candidate Epigenetic Biomarker for Coronary Artery Disease: A Multi-Dataset Discovery and Comparative Validation Study.International journal of general medicine · 2026Article
- B cells and B-cell receptor repertoire features in coronary heart disease: immunopathogenic roles, clinical relevance, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Mortality comparison in acute myocardial infarction patients according to presence versus absence of traditional modifiable cardiovascular risk factors.Bioinformation · 2026Article
- Association of Serum Fetuin-B with Large-Artery Atherosclerotic Acute Ischemic Stroke and Functional Outcome.International journal of general medicine · 2026Article
- Complement C3 in panvascular disease: a central integrator of immune signaling and vascular remodeling.Clinical science (London, England : 1979) · 2025Review
- Functional Roles of the Complement Immune System in Cardiac Inflammation and Hypertrophy.International journal of molecular sciences · 2025Review
- Heterogeneous myocardial contraction detected by speckle tracking echocardiography in systemic lupus erythematosus is associated with complement protein C4: a cross-sectional study from a Swedish tertiary referral centre.Rheumatology international · 2025Article
- Research progress on the application of nanoparticles delivery in the treatment of atherosclerosis: implications for therapeutic interventions.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewComplement system activation is implicated in various stages of atherogenesis, from fatty streak formation to plaque destabilization and thrombus formation, with its dreadful clinical sequelae such as myocardial infarction, stroke and premature death. In this review, we consider these issues and explore recent studies on complement activation in atherosclerotic plaque initiation and progression. RECENT
findingsComplement pathways impact plaque stability and healing through the modulation of inflammatory processes. Recent studies indicate that complement components, notably C3 and C5b-9, accelerate atherosclerosis progression through their interactions with endothelial cells, smooth muscle cells, and immune cells. Nonetheless, the beneficial versus deleterious effects of complement activation at different stages of atherogenesis remains a matter of ongoing debates. Research also investigates therapies targeting the complement cascade to mitigate plaque erosion and rupture. This review explores the ongoing debates surrounding complement activation in atherogenesis. We bring forward controversial findings and therapeutic strategies aimed at modulating complement cascade activation with the ultimate goal to reduce the burden of atherosclerotic cardiovascular disease.\.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.